This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence (AI), augmented reality, social media, telehealth, and other emerging technologies are changing the way that healthcare is delivered, and cosmetic dermatology is no exception. She believes some conditions, consultations, and procedures require in-person appointments to ensure safety and accuracy.
These data were presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting in Buenos Aires, Argentina. ” Icotrokinra demonstrated a favorable safety profile. In the study, 84.1% achieved a Psoriasis Area and Severity Index (PASI) 90 response, compared to 27.3% and Janssen Biotech, Inc.,
It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. The post U.S
We are confident this innovation will redefine how we think about skin health.” ” A double-blinded, randomized, placebo-controlled trial evaluated the safety and efficacy of BioRewind in 104 patients over 12-weeks.
Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.
improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.
Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. “These results also continue to validate Protagonist’s innovative peptide technology platform and its effectiveness in creating highly differentiated new chemical entities to address unmet needs in various disease areas.”
Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.
We are excited to be able to provide DEB patients with the first treatment that corrects the genetic defect and makes a true difference in their lives, says Cristina Has, MD, Professor and Head of the Genodermatoses Clinic in the Department of Dermatology at the University of Freiburg in Germany, in a news release.
” The TBA recipients include: Innovating Pain and Fatigue Management Cynthia Aranow, MD, The Feinstein Institutes for Medical Research Dr. Aranow will evaluate the use of a new, non-toxic, non-painful device that stimulates the vagus nerve to reduce pain and fatigue in people with SLE.
I am looking forward to offering my patients this new treatment option which has the potential to address their most troublesome symptoms, says Curdin Conrad, MD, a Professor of Dermatology and Head of Policlinic and the center for psoriasis at Lausanne University Hospital in Switzerland, in a news release.
New sunscreen ingredients are needed to help assuage patient safety concerns and lower skin cancer rates. Natural products such as algae and herb derivatives are also gaining traction, according to a new narrative review in the Journal of Integrative Dermatology. Innovations in Sunscreen Filters: What is on the Horizon in the US?
“Advancing the standard of care within aesthetic medicine requires us to discover and develop novel innovations into products with strong safety profiles and meaningful patient impact,” says Darin Messina, Ph.D., Senior Vice President, Aesthetics R&D, AbbVie, in a news release.
Sonelokimab is being assessed in two lead indications, HS and psoriatic arthritis (PSA), and the Company is pursuing other indications in dermatology and rheumatology. The safety profile of sonelokimab in the ARGO trial was consistent with previous trials with no new safety signals detected.
Emma Guttman-Yassky, MD, PhD , the Waldman Professor and Chair of Dermatology at Icahn Mount Sinai and the Mount Sinai Health System in New York City, has been awarded a new $6.6 NIH Grant to Study Dupilumab in Pediatric AA appeared first on The Dermatology Digest. PHOTO CREDIT: DermNet The post Mount Sinai Awarded $6.6M
We are one step closer to delivering this innovative solution to those in need and look forward to the outcomes of these filing decisions.” Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.
Novartis is the ideal partner to help us in this mission due to their unparalleled expertise in innovative medicines and their dedication to improving health outcomes,” adds Chief Medical Officer at the NFL, Dr. Allen Sills.
This represents a crucial step in offering a potential innovative treatment option to patients and their dedicated physicians, addressing a condition that is often under-recognized, under-treated and significantly impacts patients’ lives.” Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, in a news release.“
James Song, MD, FAAD, discusses how emerging topical JAK inhibitors like ruxolitinib cream may reduce the necessity for systemic therapies in select pediatric atopic dermatitis patients by effectively controlling moderate disease and potentially serving as long-term maintenance therapy with a favorable safety profile.
“The approval of JUVÉDERM VOLUMA XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs,” says Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie, in a news release. “This is the first U.S. .
“These formulations enhance overall skin texture, underscoring our commitment to integrating cutting-edge scientific research and ingredients into practical, effective skincare solutions,” says Eman Kadhim, Head of Scientific Communications & Upstream Innovation at Waldencast, in a news release.
ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile. The data was presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
“We are honored to be recognized for the 2024 People’s Choice Award by Octane’s esteemed judges, entrepreneurs and experts in dermatology and plastic surgery,” says Dina El-Sherif, MBA, founder and CEO of Trufacial, in a news release (Pictured above).
link] Peter Thomas Roth Italian American Skincare entrepreneur and founder of Peter Thomas Roth skincare brand, known for innovative solutions. It integrates the industry’s most potent laser-emitting diode with an innovative double cooling system that utilizes copper and gold macrochannels.
The safety profile of pembrolizumab in this trial was consistent with the drug’s established safety profile. The primary endpoint is RFS, and key secondary endpoints include OS and safety. The post Keytruda Disappoints in Phase III SCC Trial; Merck Halts Study appeared first on The Dermatology Digest.
The American Skin Association’s (ASA) SPOTS (Sun Protection Outreach Teaching by Students) program will receive the inaugural 2024 Research Achievement Award in Community Education/Outreach at the upcoming 2024 Society for Investigative Dermatology (SID) Annual Meeting in Dallas, TX. ” ASA Chairman, Howard P.
The Pediatric Dermatology Research Alliance (PeDRA) has awarded nearly $240K to support pediatric dermatology research across four competitive grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.
Red light therapy is considered one of the newest and most innovative skin rejuvenation procedures available. Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. Safety and Side Effects This procedure is considered safe.
The safety profile of deucravacitinib in PSORIATYK SCALP was consistent with findings in previously conducted clinical trials of deucravacitinib in psoriasis. Overall, these promising results reinforce once-daily Sotyktu as a potential oral standard of care as we continue to lead in TYK2 innovation.” versus 9.8%), pain (26.2%
2023 Highlights December 2023: The SOCS Meeting the Challenge Summit: Population Descriptors in Dermatology Research Studies. and L’Oréal Research & Innovation (Champion Level); Bristol Myers Squibb, Eli Lilly, Inc., August 2023: Dermatology Foundation and SOCS Partner to Advance Health Equity in Dermatology.
Next up, we’ll be tackling the topic of safety, coming your way in late September. IBA supports creative, innovative companies from startups to established multinational businesses of all sizes succeed in the rapidly changing, highly competitive global cosmetics and personal care industry. in both Skin Care and Hair Care.
The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.
Tattoo: The Latest Innovation One of the latest and most promising stretch mark treatments are inkless tattoos and medical stretch mark camouflage. So let’s embrace our bodies and offer our patients the opportunity to achieve confidence with these stretch mark treatments while offering innovation in the aesthetic field.
The post Meet the 2023 NEA Grant Winners appeared first on The Dermatology Digest. Ofir Cohn PhD , Boston Children’s Hospital, Boston, MA Deciphering how genetic variation associated with risk of eczema impacts human dendritic cell subset function Liwen Deng BS, PhD , President & Fellows of Harvard College, Boston, MA S.
While many clean beauty products do use natural ingredients, the focus is really on safety and effectiveness. It's like having a brainy best friend vet your products for ingredient safety and transparency. It's all about finding that sweet spot between safety and effectiveness. Another myth?
Expert Opinions on Volux According to Dr. Hadley King , a New York City-based board-certified dermatologist and clinical instructor of dermatology at the Weill Medical College of Cornell University, “Volux has more structure and cohesivity and lift capacity” than other Juvéderm fillers, such as Voluma XC.
“It all boils down to stress,” said Keira Barr, MD, who presented “Beauty & The Beast: Stress, Trauma, Skin Disease & A Somatic Approach to Healing,” during the “Mind Body Therapies as Treatment Strategy in Dermatology: What is the Evidence?” ” session at the 2023 AAD Innovation Academy in Tampa, Florida. “I
This innovative technology offers a convenient solution to the hassle of constant shaving or waxing and can be performed on various body areas such as the legs, armpits, chest, arms, and bikini area. Laser hair removal should be performed by trained and licensed professionals to ensure safety and effectiveness.
Exosomes, neurocosmetics, and supercharged actives are the most innovative — and sometimes the most controversial — skin-care trends poised to revolutionize beauty in the next few years. But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.” freeze) them.
This comprehensive guide will help you recognize red flags, ask the right questions, and prioritize your safety. In the US, legitimate practitioners often hold certifications from reputable organizations like the American Board of Plastic Surgery (ABPS) or American Academy of Dermatology (AAD).
Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. patient-years (PYs) for the safety analyses. Year 4, 0.1)
Editorial Contribution Stephen Kennedy Smith, JD, Founder and Chairman at Aramore Stephen Kennedy Smith is a cofounder of Aramore along with experts in stem cell biology, dermatology chemistry and nutrition from Harvard, MIT and UCSF. Stephen is also a principal at Park Agency- Joseph P. Sheng Li Ke Xue Jin Zhan. 2014;45(4):251-256.
It takes significant time to understand what innovative treatments are capable of and even longer to get them regulated and approved as an actual therapy. There’s tremendous excitement in the hair world and dermatology.” The real question with exosome safety has to do with your own health. I think it’s very promising.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content